Arterial Disease Multifactorial Intervention Trial (ADMIT) - Full Text View

Sponsor:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00000539

Purpose

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Condition	Intervention	Phase
Arterial Occlusive Diseases Cardiovascular Diseases Heart Diseases Vascular Diseases Diabetes Mellitus	Drug: niacin Drug: pravastatin Drug: beta-carotene Drug: vitamin E Behavioral: dietary supplements Drug: vitamin C Drug: warfarin	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Blood Thinners Dietary Supplements Heart Diseases Vascular Diseases Vitamin C Vitamin E

Drug Information available for: Carotenoids Ascorbic acid alpha-Tocopherol Niacin DL-alpha-Tocopherol Pravastatin Pravastatin sodium Warfarin Niacinamide Warfarin sodium Niacin hydrochloride Vitamin E Tocopherols Warfarin potassium Tocotrienol beta Carotene

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:	September 1992
Estimated Study Completion Date:	March 1999

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Men and women with symptomatic or asymptomatic peripheral arterial disease.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000539

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigator:

Kathryn Davis

Statistics and Epidemiology Research Corporation

More Information

Publications:

Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, Herd JA, Hunninghake DB, Sheps DS, Kostis JB, Probstfield J, Waclawiw MA, Applegate W, Elam MB. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol. 1999 Feb 15;83(4):569-75.

Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000 Sep 13;284(10):1263-70.

Garg R, Elam MB, Crouse JR 3rd, Davis KB, Kennedy JW, Egan D, Herd JA, Hunninghake DB, Johnson WC, Kostis JB, Sheps DS, Applegate WB. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J. 2000 Nov;140(5):792-803.

Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, Kennedy JW, Applegate WB. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J. 2000 Oct;140(4):631-6.

ClinicalTrials.gov Identifier:	NCT00000539 History of Changes
Other Study ID Numbers:	82
Study First Received:	October 27, 1999
Last Updated:	January 10, 2006
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Arterial Occlusive Diseases
Cardiovascular Diseases
Diabetes Mellitus
Heart Diseases
Vascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Ascorbic Acid
Vitamin E
Vitamins
Beta Carotene
Warfarin
Pravastatin
Antioxidants

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Micronutrients
Growth Substances
Anticoagulants
Hematologic Agents
Therapeutic Uses
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on February 12, 2012